Novartis Fights Enhanced Damages Bid After $178M Jury Loss

By Adam Lidgett · November 3, 2021, 6:15 PM EDT

Novartis says that it shouldn't have to pay enhanced damages after a jury hit the company with a $177.8 million verdict for selling a skin cancer drug that infringes two patents...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Case Information

Case Title

Plexxikon Inc. v. Novartis Pharmaceuticals Corporation

Case Number

Court

California Northern

Nature of Suit

Patent

Date Filed

August 03, 2017

Recent Articles By Adam

January 22, 2025
Vanda Loses Takings Clause Arguments In Trade Secret Fight
January 06, 2025
Biotech Trade Secrets Case Gets New Punitive Damages Trial
January 02, 2025
Hikma Wants Extension At High Court In Skinny Label Case
December 12, 2024
Medicare Could Lose Billions From 'Patent Abuse,' Group Says
December 09, 2024
High Court Won't Hear Zimmer Biomet Royalties Fight
November 18, 2024
Medical Group Wants Justices To Review IP Safe Harbor Fight
November 01, 2024
Jury To Decide Timing Issue In Insulin Patch Trade Secret Row
October 22, 2024
Patent Office Finds Public Engagement Leader
September 23, 2024
Fed. Circ. OKs Novartis Loss In Eye Syringe Patent Feud
July 11, 2024
Senate Clears Patent Bill Aiming To Lower Drug Prices